The role of intracellular Ca2+ in the regulation of proteinase‐activated receptor‐2 mediated nuclear factor kappa B signalling in keratinocytes
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In this study, we examined the role of Ca 2+ in linking proteinase‐activated receptor‐2 (PAR2) to the nuclear factor kappa B (NF κ B) pathway in a skin epithelial cell line NCTC2544 stably expressing PAR2 (clone G). In clone G, PAR2‐mediated NF κ B luciferase reporter activity and NF κ B DNA‐binding activity was reduced by preincubation with BAPTA‐AM but not BAPTA. Trypsin stimulation of inhibitory kappa B kinases, IKK α and IKK β, was also inhibited following pretreatment with BAPTA‐AM. BAPTA/AM also prevented PAR2‐mediated IKK α activation in cultured primary human keratinocytes. The effect of BAPTA‐AM was also selective for the IKK/NF κ B signalling axis; PAR2 coupling to ERK, or p38 MAP kinase was unaffected. Pharmacological inhibition of the Ca 2+‐dependent regulatory protein calcineurin did not inhibit trypsin‐stimulated IKK activity or NF κ B‐DNA binding; however, inhibition of Ca 2+‐dependent protein kinase C isoforms or InsP 3 formation using GF109203X or the phospholipase C inhibitor U73122, respectively, reduced both IKK activity and NF κ B‐DNA binding. Mutation of PAR2 within the C‐terminal to produce a mutant receptor, which does not couple to Ca 2+ signalling, but is able to activate ERK, abrogated NF κ B‐DNA binding and IKK activity stimulated by trypsin. These results suggest a predominant role for the InsP 3/Ca 2+ axis in the regulation of IKK signalling and NF κ B transcriptional activation. British Journal of Pharmacology (2005) 145, 535–544. doi:10.1038/sj.bjp.0706204
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions
Seiberg, M., Paine, C., Sharlow, E., Andrade-Gordon, P., Costanzo, M., Eisinger, M., & Shapiro, S. S. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4692 · Cited by 238 · cited 1×
“Again, the receptor is strongly implicated in inflammatory responses in this tissue (Wakita et al., 1997), being linked with disease states such as type IV dermatitis (Kawagoe et al., 2002), and also in the control of skin pigmentation (Seiberg et al., 2000).”
Background
Cited by
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Role for protease activity in visceral pain in irritable bowel syndrome
Cenac, N., Andrews, C. N., Holzhausen, M., Chapman, K., Cottrell, G., Andrade-Gordon, P., Steinhoff, M., Barbara, G., Beck, P., Bunnett, N. W., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29255 · Cited by 591
Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more
Ramachandran, R., & Hollenberg, M. D. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707507 · Cited by 305
Protease-activated receptor 2 signaling in inflammation
Rothmeier, A. S., & Ruf, W. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0289-1 · Cited by 289
Vroling, A. B., Jonker, M. J., Luiten, S., Breit, T. M., Fokkens, W. J., & van Drunen, C. M. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0278oc · Cited by 49
Metadata
- Authors
- Macfarlane, S. R., Sloss, C. M., Cameron, P., Kanke, T., McKenzie, R. C., & Plevin, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 145
- Issue
- 4
- Pages
- 535-544
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1547828694
- Cited by
- 62
- References
- 1
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.